Literature DB >> 15161717

Confirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukemia, including cases with chromosome 17p deletions and without detectable CD25 expression.

Susan J Morgan, John F Seymour, H Miles Prince, David A Westerman, Max M Wolf.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15161717

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  4 in total

1.  A denileukin diftitox (Ontak) associated retinopathy?

Authors:  J B Ruddle; C A Harper; D Hönemann; J F Seymour; H M Prince
Journal:  Br J Ophthalmol       Date:  2006-08       Impact factor: 4.638

Review 2.  Targeting regulatory T cells.

Authors:  Christine Ménétrier-Caux; Tyler Curiel; Julien Faget; Manuarii Manuel; Christophe Caux; Weiping Zou
Journal:  Target Oncol       Date:  2012-02-12       Impact factor: 4.493

3.  IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.

Authors:  Mary T Litzinger; Romaine Fernando; Tyler J Curiel; Douglas W Grosenbach; Jeffrey Schlom; Claudia Palena
Journal:  Blood       Date:  2007-07-06       Impact factor: 22.113

4.  Targeted treatment for chronic lymphocytic leukemia.

Authors:  Aisha Masood; Taimur Sher; Aneel Paulus; Kena C Miller; Kasyapa S Chitta; Asher Chanan-Khan
Journal:  Onco Targets Ther       Date:  2011-11-04       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.